For the quarter ending 2025-09-30, DVAX had $61,146K increase in cash & cash equivalents over the period. $32,592K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenues | 94,876 | - |
| Cost of sales - product | 14,403 | - |
| Research and development | 19,116 | - |
| Selling and marketing | 21,791 | - |
| General and administrative | 18,295 | - |
| Other segment items | -5,656 | - |
| Net (loss) income | 26,927 | -77,378 |
| Depreciation and amortization | 1,291 | 2,415 |
| Amortization of right-of-use assets | 803 | 1,660 |
| Inventory write off | -338 | 3,976 |
| Sublease termination loss (note 5) | 0 | 0 |
| Accretion of discounts on marketable securities | 1,199 | 3,835 |
| Stock-based compensation expense | 12,390 | 27,434 |
| Bad debt expense | 0 | 10,970 |
| Non-cash interest expense | -2,513 | 3,333 |
| Loss on debt extinguishment | 0 | -82,095 |
| Accounts and other receivables, net | -24 | 26,439 |
| Inventories | -2,737 | 9,609 |
| Prepaid manufacturing | 0 | - |
| Prepaid expenses and other current assets | -3,335 | 5,595 |
| Other assets | 0 | - |
| Accounts payable | 1,355 | -6,503 |
| Lease liabilities | -999 | -2,152 |
| Accrued and other liabilities | -9,984 | 3,420 |
| Net cash provided by operating activities | 33,829 | 3,792 |
| Purchases of marketable securities | 139,862 | 111,793 |
| Proceeds from maturities and redemption of marketable securities | 168,422 | 218,875 |
| Purchases of property and equipment, net | 1,237 | 5,380 |
| Net cash provided by (used in) investing activities | 27,323 | 101,702 |
| Proceeds from issuance of convertible notes (note 7) | 0 | 39,708 |
| Payment for debt issuance costs (note 7) | 0 | 4,500 |
| Payments for debt extinguishment (note 7) | 0 | 80,938 |
| Proceeds from unwind of capped call options (note 7) | 0 | 46,554 |
| Payments for repurchase of common stock (note 11) | 572 | 100,635 |
| Proceeds from exercise of stock options | 95 | 6,738 |
| Proceeds from employee stock purchase plan | 664 | 835 |
| Payments for taxes related to net share settlement of restricted and performance stock units | 248 | 11,562 |
| Net cash used in financing activities | -61 | -103,800 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | 55 | 1,558 |
| Net increase (decrease) in cash and cash equivalents, and restricted cash | 61,146 | 3,252 |
| Cash and cash equivalents at beginning of period | 96,154 | - |
| Cash and cash equivalents at end of period | 160,552 | - |
DYNAVAX TECHNOLOGIES CORP (DVAX)
DYNAVAX TECHNOLOGIES CORP (DVAX)